Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia Therapy
Research results from Center for Drug Evaluation and Research update understanding of acute lymphoblastic leukemia therapy
March 16th, 2008
A report, 'Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate,' is newly published data in Clinical Cancer Research. According to recent research published in the journal Clinical Cancer Research, "On June 28, 2006, the U.S. Food and Drug Administration approved dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine kinases, for the treatment of adults with chronic phase, accelerated phase, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) with...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-16)
|
